Hemophilia Market Analysis By Type (Hemophilia A, Hemophilia B, Hemophilia C), By Treatment (On-demand, Prophylaxis), By Therapy (Replacement Therapy, Immune Tolerance Induction [ITI] Therapy, Gene Therapy), And Segment Forecasts to 2024

Description: Global hemophilia market is expected to reach USD 15.2 billion by 2024, according to this new report. Increasing need for diagnosis of the target population in order to initiate prophylaxis treatment and supportive government programs is expected to be the vital impact rendering driver.

The market players are predicted to adopt strategies such as pipeline product development and geographic expansion in underdeveloped and developing regions, such as Middle Eastern and West African countries.

As of 2015, federal bodies such as the World Federation Hemophilia have vast information and treatment regulation in about 172 countries, of which 20 were added in 2013, including Nigeria, Togo, Mali, Zambia, Mauritania, and others.

Competitive pricing strategy is a vital factor promoting market players' growth over the forecast period. For instance, Biogen launched Eloctate in 2014 in the U.S. at a lower price than the existing vastly used drug Advate.

Further Key Findings From the Study Suggest:

Hemophilia B is expected to grow at a rapid rate of over 6.0% during the forecast period. Higher emphasis on pipeline products with an extended half-life and increasing incidence of hemophilia B affected patients are expected to be the prominent growth factors.

On-demand treatment dominated the segment over the forecast period and is expected to contribute more than 50.0% by 2024. However, prophylaxis is expected to be the fastest growing segment because of the requirement for better control of bleeding episodes and growing financial assistance programs by healthcare providers and industry players.

For instance, Grifols has launched the “AlphaNine SD Copay Card” and “ALPHANATE Copay Program” for immediate enrollment in prophylaxis treatment by patients.

On the basis of therapy, gene therapy is expected to be the fastest growing segment as a result of increasing R&D and innovations in the field. Furthermore, replacement therapy is expected to witness lucrative growth due to the launch of extended half-life versions of currently available drugs.

For instance, Novo Nordisk is working on N8-GP, CSL Behring is working on CSL689 rVIIa-FP, and Bayer is working on BAY 94-9027. These are expected to be commercially available around 2017/2018. This is expected to improve treatment over the forecast period thereby boosting growth.

Major market players include Biogen, Novo Nordisk, Baxalta, Octapharma, CSL Behring, Pfizer, Inc., and Bayer Healthcare. Most of the companies are actively involved in the awareness and treatment programs launched by regional governments and hemophilia associations. Majority of their products that are awaiting FDA approval have extended therapeutic use in adults as well as children.

Contents:

1. Methodology And Scope
   1.1. Research Methodology
   1.2. Research Scope & Assumptions
   1.3. List of Data Sources

2. Executive Summary
3. Hemophilia Industry Outlook
   3.1. Market Segmentation
   3.2. Market Size and Growth Prospects
   3.3. Hemophilia: Market Dynamics
       3.3.1. Market driver analysis
       3.3.2. Market restraint analysis
   3.4. Key Opportunities Prioritized
   3.5. Industry Analysis: Porter’s

4. Hemophilia Type Outlook
   4.1. Hemophilia Market Share by Type, 2015 & 2024
   4.2. Hemophilia A
       4.2.1. Hemophilia A market estimates and forecasts, 2013 - 2024 (USD Million)
   4.3. Hemophilia B
       4.3.1. Hemophilia B market estimates and forecasts, 2013 - 2024 (USD Million)
   4.4. Hemophilia C
       4.4.1. Hemophilia C market estimates and forecasts, 2013 - 2024 (USD Million)
   4.5. Others
       4.5.1. Others market estimates and forecasts, 2013 - 2024 (USD Million)

5. Hemophilia Treatment Outlook
   5.1. Hemophilia Market Share by Treatment, 2015 & 2024
   5.2. On-demand
       5.2.1. On-demand based hemophilia market estimates and forecasts, 2013 - 2024 (USD Million)
   5.3. Prophylaxis
       5.3.1. Prophylaxis-based hemophilia market estimates and forecasts, 2013 - 2024 (USD Million)

6. Hemophilia Therapy Outlook
   6.1. Hemophilia Market Share by Therapy, 2015 & 2024
   6.2. Recombinant Therapy
       6.2.1. Recombinant therapy-based hemophilia market estimates and forecasts, 2013 - 2024 (USD Million)
   6.3. Immune Tolerance Induction (ITI) Therapy
       6.3.1. ITI therapy-based hemophilia market estimates and forecasts, 2013 - 2024 (USD Million)
   6.4. Gene Therapy
       6.4.1. Gene therapy-based hemophilia market estimates and forecasts, 2013 - 2024 (USD Million)

7. Hemophilia Regional Outlook
   7.1. Hemophilia Market Share by Region, 2015 & 2024
   7.2. North America
       7.2.1. North America market estimates and forecasts, by type, 2013 - 2024 (USD Million)
       7.2.2. North America market estimates and forecasts, by treatment, 2013 - 2024 (USD Million)
       7.2.2.1. U.S. market estimates and forecasts
       7.2.2.2. Canada market estimates and forecasts
   7.3. Europe
       7.3.1. Europe market estimates and forecasts, by type, 2013 - 2024 (USD Million)
       7.3.2. Europe market estimates and forecasts, by treatment, 2013 - 2024 (USD Million)
       7.3.2.1. UK market estimates and forecasts
       7.3.2.2. Germany market estimates and forecasts
   7.4. Asia-Pacific
       7.4.1. Asia-Pacific market estimates and forecasts, by type, 2013 - 2024 (USD Million)
       7.4.2. Asia-Pacific market estimates and forecasts, by treatment, 2013 - 2024 (USD Million)
       7.4.2.1. Japan market estimates and forecasts
       7.4.2.2. China market estimates and forecasts
   7.5. Latin America
       7.5.1. Latin America market estimates and forecasts, by type, 2013 - 2024 (USD Million)
       7.5.2. Latin America market estimates and forecasts, by treatment, 2013 - 2024 (USD Million)
       7.5.2.1. Brazil market estimates and forecasts
       7.5.2.2. Mexico market estimates and forecasts
   7.6. Middle East and Africa (MEA)
       7.6.1. MEA market estimates and forecasts, by type, 2013 - 2024 (USD Million)
       7.6.2. MEA market estimates and forecasts, by treatment, 2013 - 2024 (USD Million)
7.6.2.1. South Africa market estimates and forecasts
7.6.2.2. Saudi Arabia market estimates and forecasts

8. Competitive Landscape
8.1. Novo Nordisk
8.1.1. Company profile
8.1.2. Financial performance
8.1.3. Product portfolio
8.1.4. Strategic initiatives
8.2. Biogen
8.2.1. Company profile
8.2.2. Financial performance
8.2.3. Product portfolio
8.2.4. Strategic initiatives
8.3. Chugai Pharmaceutical Co.
8.3.1. Company profile
8.3.2. Financial performance
8.3.3. Product portfolio
8.3.4. Strategic initiatives
8.4. Bayer Healthcare
8.4.1. Company profile
8.4.2. Financial performance
8.4.3. Product portfolio
8.4.4. Strategic initiatives
8.5. Pfizer, Inc.
8.5.1. Company profile
8.5.2. Financial performance
8.5.3. Product portfolio
8.5.4. Strategic initiatives
8.6. Shire Plc.
8.6.1. Company profile
8.6.2. Financial performance
8.6.3. Product portfolio
8.6.4. Strategic initiatives
8.7. Baxalta
8.7.1. Company profile
8.7.2. Financial performance
8.7.3. Product portfolio
8.7.4. Strategic initiatives
8.8. CSL Behring
8.8.1. Company profile
8.8.2. Financial performance
8.8.3. Product portfolio
8.8.4. Strategic initiatives
8.9. Octapharma
8.9.1. Company profile
8.9.2. Financial performance
8.9.3. Product portfolio
8.9.4. Strategic initiatives

List of Tables

Table 1 Hemophilia market - Industry summary & key buying criteria
Table 2 Hemophilia market, by type, 2013 - 2024 (USD Million)
Table 3 Hemophilia market, by treatment, 2013 - 2024 (USD Million)
Table 4 Hemophilia market, by therapy, 2013 - 2024 (USD Million)
Table 5 Hemophilia market, by region, 2013 - 2024 (USD Million)
Table 6 Hemophilia market- Key market driver analysis
Table 7 Hemophilia market- Key market restraint analysis
Table 8 North America hemophilia market, by type 2013 - 2024 (USD Million)
Table 9 North America hemophilia market, by treatment 2013 - 2024 (USD Million)
Table 10 North America hemophilia market, by therapy 2013 - 2024 (USD Million)
Table 11 U.S. hemophilia market, by type 2013 - 2024 (USD Million)
**Fax Order Form**

To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit [http://www.researchandmarkets.com/contact/](http://www.researchandmarkets.com/contact/)

**Order Information**

Please verify that the product information is correct and select the format(s) you require.

**Product Name:** Hemophilia Market Analysis By Type (Hemophilia A, Hemophilia B, Hemophilia C), By Treatment (On-demand, Prophylaxis), By Therapy (Replacement Therapy, immune Tolerance Induction [ITI] Therapy, Gene Therapy), And Segment Forecasts to 2024

**Web Address:** [http://www.researchandmarkets.com/reports/3822888/](http://www.researchandmarkets.com/reports/3822888/)

**Office Code:** SCWP9WN9

**Product Formats**

Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 4950</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users</td>
<td>USD 7950</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 9950</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

**Contact Information**

Please enter all the information below in **BLOCK CAPITALS**

<table>
<thead>
<tr>
<th>Title: Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td>Last Name:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World